<DOC>
	<DOC>NCT00568607</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy and tolerability of the combination chemotherapy of DICE in the patients with NK/T cell lymphoma.</brief_summary>
	<brief_title>Study on the Combination Regimen of Dexamethasone Ifosfamide Cisplatin Etoposide in Patients With NK/T Cell Lymphoma</brief_title>
	<detailed_description>Patients with NK/T cell lymphoma usually have a bad prognosis. These patients cannot be treated successfully with the conventional chemotherapy of CHOP.The investigators did this trial to evaluate the efficacy and tolerability of the combination chemotherapy of DICE in the patients with NK/T cell lymphoma.</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, T-Cell</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>Age range 1875 years old Histological confirmed NK/T cell lymphoma ECOG performance status less than 2 Life expectancy of more than 3 months None of major drugs in the trial (IFO,VP16,DDP) has been previously used Normal laboratory values: hemoglobin &gt; 80 g/dl, neutrophil &gt; 2×109/L, platelet &gt; 100×109/L, serum creatine &lt; 1.5×upper limitation of normal (ULN), serum bilirubin &lt; 1.5×ULN, ALT and AST &lt; 2.5×ULN Pregnant or lactating women Serious uncontrolled diseases and intercurrent infection The evidence of CNS metastasis History of other malignancies except cured basal cell carcinoma of skin and carcinoma insitu of uterine cervix</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>NK/T cell lymphoma</keyword>
	<keyword>Response Rate</keyword>
	<keyword>TTP</keyword>
	<keyword>OS</keyword>
	<keyword>Toxicities</keyword>
</DOC>